Rebeccamycin Analog in Treating Children With Relapsed or Refractory Neuroblastoma
- Conditions
- Neuroblastoma
- Registration Number
- NCT00003737
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Brief Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of rebeccamycin analog in treating children who have relapsed or refractory neuroblastoma.
- Detailed Description
OBJECTIVES:
* Determine the response rate to rebeccamycin analogue in children with relapsed or refractory neuroblastoma.
* Determine the toxicity of this drug in these patients.
* Identify and establish in vitro biologic correlates of clinical responses and toxicity of this drug in these patients.
OUTLINE: Patients receive rebeccamycin analogue IV over 1 hour once on days 1-5. Treatment repeats every 3 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity.
PROJECTED ACCRUAL: This study will accrue up to 30 patients within 1.5 years.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 30
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Response (complete response, very good partial response, or partial response) Freedom from progression Time to treatment failure
- Secondary Outcome Measures
Name Time Method Toxicity
Trial Locations
- Locations (1)
Memorial Sloan-Kettering Cancer Center
🇺🇸New York, New York, United States